Cancer Immunology Training Program

项目摘要 对癌症免疫学的兴趣从未如此强烈。抑制性受体的突破性观察 阻断，结合使用嵌合抗原受体（CAR）修饰的T 细胞过继疗法强调了进一步进行癌症基础和转化研究的迫切需要 免疫学虽然潜在免疫靶点的管道正在增长，但未来癌症的管道 免疫学家是有限的，部分原因是工业和学术界的巨大需求。迫切需要掌握 培训计划，为下一代癌症免疫学家做好最佳准备。令人惊讶的是，我们的巨蟹座 匹兹堡大学医学院（UPSOM）的免疫学培训计划（CITP）是唯一一个 六个国家癌症研究所支持的T32完全专注于癌症免疫学。这使得我们的计划 独特而重要。CITP，其中有5个前-和3个博士后插槽，是在其第20个年头，我们正在寻求 支持未来五年。CITP的目标是为研究生、研究员和医生提供 科学家与课程，研究项目，特殊的环境和资源，以及高素质的导师 这将使他们能够：（1）对本报告所涵盖的五个研究重点领域之一作出重大贡献 培训计划：（a）肿瘤微环境（TME）中的抑制机制，（B）适应性免疫和 TME内的细胞相互作用，（c）先天、环境和代谢调节，（d）促进免疫 对肿瘤的反应：基于细胞的疗法和疫苗，以及（e）系统癌症免疫学;（2）获得清晰的 了解与癌症免疫学相关的细胞和分子机制;（3）获得实用的 了解人类癌症的免疫学;（4）获得对所有领域的清晰概念性理解， 影响癌症免疫学;（5）发展关键职业技能和管理能力。深思熟虑地建立在 什么是一个行之有效的培训计划，我们已经作出了一些改进，如增加癌症， 免疫学-我们的教师的焦点（共25）。UPSOM和HCC已经并将继续进行前所未有的 癌症免疫学的投资。该培训计划利用UPSOM的特殊优势，包括 卓越的NCI综合癌症中心，强大的免疫中心转化研究基地， 杰出的免疫学系，支持强大的基础研究和我们的研究生研究计划 （PMI）。UPSOM实施了有效的计划，以确保出色的培训，重点是增加 征聘和留住妇女和统一登记管理人员。我们的申请人池是特殊的，由于我们的成功， PMI和MSTP研究生课程，备受追捧的临床奖学金和优秀的导师库。超过 在过去5年中，CITP招收了24名受训人员（15岁前; 9岁后），其中13名是妇女（54%），3名是 URM（12.5%）。最后，我们的学员在获得校外/竞争力方面非常成功。 奖学金（共14个[58%]：F99/K 00 [1]，F32 [3]，F31 [4]，F30 [3]，Damon-Runyon [1]，St. Baldrick's [1]， Hartwell [1]）。我们很高兴并渴望培养下一代癌症免疫学家。

PROJECT SUMMARY Interest in cancer immunology has never been more intense. Breakthrough observations with inhibitory receptor blockade, combined with ground breaking advances in the use of chimeric antigen receptor (CAR)-modified T cell adoptive therapies have highlighted the critical need to further basic and translation research in cancer immunology. While the pipeline of potential immunotherapeutic targets is growing, the pipeline of future cancer immunologists is limited, in part due to significant demand in industry and academia. There is a critical need for training programs that optimally prepare the next generation of cancer immunologists. Surprisingly, our Cancer Immunology Training Program (CITP) at the University of Pittsburgh School of Medicine (UPSOM) is one of only six NCI-supported T32s nationwide that focus entirely on cancer immunology. This makes our program unique and essential. CITP, which has 5 pre- and 3 post-doctoral slots, is in its 20th year and we are seeking support for the next five years. The goals of the CITP are to provide graduate students, fellows and physician scientists with courses, research projects, exceptional environment and resources, and highly-qualified mentors that will allow them to: (1) make a significant contribution to one of five areas of research focus covered by this training program: (a) Inhibitory Mechanisms in the Tumor Microenvironment (TME), (b) Adaptive Immunity and Cellular Interactions within the TME, (c) Innate, Environmental and Metabolic Modulation, (d) Promoting Immune Responses to Tumors: Cell-Based Therapies & Vaccines, and (e) Systems Cancer Immunology; (2) gain a clear understanding of the cellular and molecular mechanisms relevant to cancer immunology; (3) obtain a practical understanding of the immunology of human cancer; (4) gain a clear conceptual understanding of all areas that impact cancer immunology; and (5) develop critical career skills and managerial ability. Building thoughtfully on what is a proven training program, we have made several enhancements, such as increasing the cancer immunology-focus of our faculty (25 total). UPSOM and HCC have and continue to make an unprecedented investment in cancer immunology. The training program exploits particular strengths at UPSOM, including an exceptional NCI Comprehensive Cancer Center, a strong immuno-centric translational research base, an outstanding Immunology Department that underpins strong basic research, and our graduate research program (PMI). UPSOM has implemented effective programs to ensure outstanding training, with emphasis on increasing the recruitment and retention of women and URMs. Our applicant pool is exceptional due to the success of our PMI and MSTP graduate programs, highly sought-after clinical fellowships, and outstanding mentor pool. Over the last 5 years, CITP has enrolled 24 trainees (Pre – 15; Post – 9), of which 13 were women (54%) and 3 were URM (12.5%). Lastly, our trainees have been extremely successful in obtaining extramural/competitive fellowships (14 total [58%]: F99/K00 [1], F32 [3], F31 [4], F30 [3], Damon-Runyon [1], St. Baldrick's [1], Hartwell [1]). We are excited and eager to train the next generation of cancer immunologists.